The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis

The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis

IntroductionOur meta-analysis aimed to evaluate the diagnostic value of 18F-DCFPyL prostate-specific membrane antigen (PSMA) PET in patients with suspected prostate cancer.MethodsWe searched for articles that evaluate the diagnostic value of 18F-DCFPyL PSMA PET in patients with suspected prostate ca...

Full description

Bibliographic Details
Main Authors:	Wenyang Pang, Shulin Cheng, Zhongbo Du, Shuang Du
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Oncology
Subjects:	18F-DCFPyL PSMA PET prostate cancer diagnostic performance meta-analysis systemic review and meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1145759/full

Similar Items

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
by: Ke-Hao Pan, et al.
Published: (2021-02-01)

18F-DCFPyL PET/CT in primary staging of prostate cancer
by: Maurits Wondergem, et al.
Published: (2018-10-01)

Salivary excretion of systemically injected [18F]DCFPyL in prostate cancer patients undergoing PSMA scans
by: Bruna Fernandes, et al.
Published: (2024-04-01)

Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
by: Gonçalo Ferreira, et al.
Published: (2019-05-01)

18F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
by: Ur Metser, et al.
Published: (2022-10-01)

Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay
by: Medhat M. Osman, et al.
Published: (2021-04-01)

Detection Rate of <sup>18</sup>F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
by: Giorgio Treglia, et al.
Published: (2019-05-01)

Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes
by: Dae-Myoung Yang, et al.
Published: (2021-10-01)

Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on <sup>18</sup>F-DCFPyL PET/CT Scans
by: Tushar Garg, et al.
Published: (2022-10-01)

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis
by: Jiale Sun, et al.
Published: (2021-04-01)

<sup>18</sup>F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center
by: Ur Metser, et al.
Published: (2021-08-01)

Comparative study of 18F-DCFPyL PET/CT and 99mTc-MDP SPECT/CT bone imaging for the detection of bone metastases in prostate cancer
by: Xiongjian Hu, et al.
Published: (2023-07-01)

PSMA-Targeted PET Radiotracer [18F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease
by: Ismail MS, et al.
Published: (2023-12-01)

Higher Preoperative Maximum Standardised Uptake Values (SUV<sub>max</sub>) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]DCFPyL Positron Emission Tomography/Computed Tomography
by: Katelijne C. C. de Bie, et al.
Published: (2023-07-01)

Head-to-Head Comparison of [<sup>18</sup>F]F-choline and Imaging of Prostate-Specific Membrane Antigen, Using [<sup>18</sup>F]DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer
by: Laura García-Zoghby, et al.
Published: (2023-06-01)

Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007
by: Stephanie Robu, et al.
Published: (2018-04-01)

18F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
by: Shuoming Zhou, et al.
Published: (2022-02-01)

18F DCFPyL PSMA avid biopsy proven subcutaneous capillary haemangioma as a malignancy mimic in the setting of biochemical recurrent prostate carcinoma
by: Manvinder Dhillon, MBBS, BMedSci, PGDAAD, MS, et al.
Published: (2022-06-01)

The performance of 18F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis
by: Zhi-Qiang Qin, et al.
Published: (2022-01-01)

Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
by: Jyoti Roy, et al.
Published: (2021-07-01)

18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
by: Aruz Mesci, et al.
Published: (2023-03-01)

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
by: Jan Heilinger, et al.
Published: (2023-09-01)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
by: Eugene Shenderov, et al.
Published: (2018-03-01)

Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses
by: Salvatore Annunziata, et al.
Published: (2020-08-01)

Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis
by: Xue Liu, et al.
Published: (2022-07-01)

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT
by: Ryan M. Phillips, et al.
Published: (2018-01-01)

Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis
by: Xu Bin, et al.
Published: (2020-01-01)

Detection of Biochemically Recurrent Prostate Cancer with [<sup>18</sup>F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters
by: Mohammad S. Sadaghiani, et al.
Published: (2023-08-01)

Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer
by: Sarah Piron, et al.
Published: (2020-02-01)

PET/CT imaging 2 h after injection of [18F]PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h
by: Erland Hvittfeldt, et al.
Published: (2023-05-01)

Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer
by: Xing Zhou, et al.
Published: (2021-02-01)

Comparing [18F]FET PET and [18F]FDOPA PET for glioma recurrence diagnosis: a systematic review and meta-analysis
by: Pengbo Yu, et al.
Published: (2024-01-01)

Application of 18F-PSMA-1007 PET/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels ≤ 0.5 ng/mL
by: Małgorzata Mojsak, et al.
Published: (2023-08-01)

Diagnostic accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography for suspected primary and postoperative pyogenic spondylitis
by: Qingyu Zhang, et al.
Published: (2023-01-01)

The utility of 18F-FDG PET and PET/CT in the diagnosis and staging of chondrosarcoma: a meta-analysis
by: Qingyu Zhang, et al.
Published: (2020-06-01)

Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
by: Wenxiao Yu, et al.
Published: (2023-08-01)

Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [<sup>18</sup>F]F-PSMA 1007 PET
by: Elisabeth Relt, et al.
Published: (2022-10-01)

Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
by: Melanie Hohberg, et al.
Published: (2019-07-01)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with <sup>68</sup>Ga-PSMA PET/CT Features in Primary Staging
by: Luigia Vetrone, et al.
Published: (2023-03-01)

Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
by: Salam Awenat, et al.
Published: (2021-03-01)